All In Biotech

Drug Trial Radar · NCT06799845

Phase 2B Study Assessing Pain Relief After Replacement of the Knee

A Phase 2B, Randomized, Double Blind, Placebo and Active Comparator Controlled, Multicenter, Safety, and Efficacy Trial of ATX101 in Adults Undergoing Total Knee Arthroplasty

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

226

Actual

Start

Feb 3, 2025

Primary completion

Oct 3, 2025

Study completion Oct 3, 2025

Sponsor

Lead sponsor
Allay Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the ATX101-TKA-004 clinical trial aims to evaluate the efficacy and safety of ATX101 1,500 mg in participants undergoing primary unilateral total knee arthroplasty. The study will compare the effectiveness of ATX101 with a saline placebo and bupivacaine, an active comparator. Additionally, it will assess opioid consumption among participants receiving ATX101 versus those given the saline placebo and bupivacaine. The trial will also focus on the safety and tolerability of ATX101 in the participants.

Conditions

  • Total Knee Arthroplasty (Postoperative Pain)

Interventions

  • ATX101Drug

    ATX101 bupivacaine implants, total of 1,500 mg into the surgical site

  • bupivacaine hydrochlorideDrug

    bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration

  • saline placeboDrug

    normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to PlaceboTime frame: from 30 minutes through 168 hours (Day 8)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Woodland International Research Group, LLC

    Little Rock, Arkansas

  • Phoenix Clinical Research

    Tamarac, Florida

  • Atlanta Centre for Medical Research

    Atlanta, Georgia

  • NextStage Clinical Research

    Wichita, Kansas

  • Chesapeake Research Group, LLC

    Pasadena, Maryland

  • First Surgical Hospital

    Bellaire, Texas

  • Legent Orthopedic Hospital

    Carrollton, Texas

  • Memorial Hermann Village

    Houston, Texas

  • Endeavor Clinical Trials, LLC

    San Antonio, Texas

  • NextStage Clinical Research

    San Antonio, Texas

  • JBR Clinical Research, LLC

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.